Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Melanoma × Rituximab × Clear all

Phase

Status

Unknown 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 62 Lymphoma, Large B-Cell, Diffuse 61 Lymphoma 58 Lymphoma, Follicular 54 Leukemia, Lymphocytic, Chronic, B-Cell 54 Lymphoma, B-Cell, Marginal Zone 27 Burkitt Lymphoma 27 Lymphoma, Mantle-Cell 23 Lymphoma, B-Cell 22 Waldenstrom Macroglobulinemia 21 Precursor Cell Lymphoblastic Leukemia-Lymphoma 21 Leukemia 19 Recurrence 16 Neoplasms 10 Hodgkin Disease 10 Lymphoma, Large-Cell, Immunoblastic 9 Multiple Myeloma 8 Leukemia, Prolymphocytic 8 Leukemia, Myeloid, Acute 8 Myelodysplastic Syndromes 7 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5 Neoplasms, Plasma Cell 5 Mycosis Fungoides 5 Lymphoma, T-Cell, Cutaneous 5 Leukemia, Hairy Cell 5 Dendritic Cell Sarcoma, Interdigitating 5 Sezary Syndrome 4 Lymphoproliferative Disorders 4 Lymphoma, Large-Cell, Anaplastic 4 Lymphoma, Extranodal NK-T-Cell 4

Interventions

pembrolizumab 45 Ipilimumab 39 Cyclophosphamide 38 Nivolumab 33 aldesleukin 26 fludarabine 19 Vemurafenib 19 Interleukin-2 19 dabrafenib 15 Temozolomide 15 fludarabine phosphate 13 trametinib 12 Radiosurgery 9 Dacarbazine 9 spartalizumab 8 cobimetinib 8 binimetinib 8 Radiotherapy 8 poly ICLC 6 encorafenib 6 Introns 6 CTLA-4 Antigen 6 Biopsy 6 montanide ISA 51 5 atezolizumab 4 Interferon alpha-2 4 Immunohistochemistry 4 Celecoxib 4 Bevacizumab 4 tovorafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01032122 2013-04-25

Rituximab in Metastatic Melanoma

Medical University of Vienna

Phase 1 Terminated

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡